-
Media ReleaseNovartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren
-
Media ReleaseNovartis schliesst Vereinbarung zum Erwerb von AveXis Inc. für USD 8,7 Mrd ab, um Therapie der SMA zu transformieren und Position als führendes Gentherapie-und Neuroscience-Unternehmen auszubauen
-
Media ReleaseNovartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
-
Media ReleaseNovartis tender offer for AveXis commences
-
Media ReleaseNovartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
-
Media ReleaseNovartis provides update on proposed acquisition of AveXis
-
Media ReleaseSandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
-
Media ReleaseNovartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
-
Media ReleaseNovartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
-
Media ReleaseNovartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
-
Media ReleaseNovartis annonce son intention de solliciter l'approbation des actionnaires pour la scission à 100% d'Alcon, sa division de produits ophtalmologiques, et initie un rachat d'actions à hauteur d'USD ...
-
Media ReleaseNovartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn